The effect of CLA in patients with Non-alcohlic fatty liver disease.

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 46

Inclusion Criteria

Verification of having NAFLD (based on liver ultrasound and liver enzyme levels above normal values ??based on kits used); 20-50 years old; BMI=30-40; takeing 400IU vitamin E daily.
Exclusion criteria: Consumption of alcohol; Pregnancy or lactation and menopause; being athleteic; Inflammatory conditions such as infection; history or perceive of hypertension; Family history of hyperlipidemia; history or perceive of cardiovascular disease; history or perceive of lung disease; history or perceive of renal disease; Liver transplantation; Acute or chronic disorders and other diseases of the liver (hepatitis B, C and liver infections, etc.); Biliary disease; Known Autoimmune disease; Cancer; An inherited disorder affecting the liver status (iron and copper storage disease, etc.); Perceive diseases such as burns and injury during the study; surgery in last 3 months; the use of some medications such as antihypertensitives, insulin sensitivity enhancer, hepatotoxic drugs , statines; Taking any vitamins, minerals and antioxidant supplementation in the last two months; Taking contraceptive pills and estrogen; Consumption of flaxseed; consumption of nuts more than 3 per day .

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Resistin. Timepoint: Beginning and end of the intervention. Method of measurement: Elisa.;Inflammatory factors(IL-6,Il-10,TNFa,hs-CRP). Timepoint: Begining and end of the study. Method of measurement: IL-6,Il-10,TNFa: Elisa and hs-CRP : immunoturbidimetry.;Insulin resistance and Insulin sensitivity. Timepoint: Beginning and end of the intervention. Method of measurement: Insulin resistance with HOMA-IR index and Insulin sensitivity with Quicki index.;Liver enzymes(AST-ALT-ALP). Timepoint: Beginning and end of the intervention. Method of measurement: IFCC.;Lipid profile. Timepoint: Beginning and end of the intervention. Method of measurement: Spectrophotometry and Friedewald Formula for LDL.;Oxidative Stress Indicies(TAC-ARE-MDA). Timepoint: Beginning and end of the intervention. Method of measurement: TAC and ARE : spectrophotometry and MDA : thiobarbituric acid.;?Sonography faindings. Timepoint: Beginning and end of the intervention. Method of measurement: Liver Sonography.

Secondary Outcome Measures

Name	Time	Method
Anthropometry(BMI-WC-WHR-WHtR). Timepoint: Beginning, second, fourth, sixth and end of the intervention. Method of measurement: metr, scale and stadiometr.;Body composition. Timepoint: Beginning and end of the intervention. Method of measurement: BIA.;Energy and nutrient intake. Timepoint: beginning, fourth week and end of the intervention. Method of measurement: 3 day food record.;Comparison of physical activity. Timepoint: beginning, fourth week and end of the intervention. Method of measurement: Physical Activity Questionnaire.